Telomir Pharmaceuticals (NASDAQ:TELO) Issues Quarterly Earnings Results

Telomir Pharmaceuticals (NASDAQ:TELO) posted its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports.

Telomir Pharmaceuticals Trading Up 8.2 %

Telomir Pharmaceuticals stock traded up $0.34 during mid-day trading on Tuesday, hitting $4.51. The company had a trading volume of 128,303 shares, compared to its average volume of 114,327. Telomir Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $20.72. The stock’s 50 day moving average price is $4.74 and its two-hundred day moving average price is $4.81.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.